ID

13154

Beschreibung

A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00559091

Link

https://clinicaltrials.gov/show/NCT00559091

Stichworte

  1. 20.01.16 20.01.16 -
Rechteinhaber

CC BY-NC 3.0

Hochgeladen am

20. Januar 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Acute Myelocytic Leukemia NCT00559091

Eligibility Acute Myelocytic Leukemia NCT00559091

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
a diagnosis of acute myeloid leukemia (aml), either m4 or m5 subtype de novo or resulting from a transformation from mds or a myeloproliferative disorder.
Beschreibung

AML diagnosis

Datentyp

boolean

Alias
UMLS CUI [1]
C0023467
patients with aml who (a) have failed primary therapy -defined as failing two induction chemotherapies, (b) have relapsed or (c) are not suitable for intensive induction chemotherapy will be eligible. or
Beschreibung

patients with aml who (a) have failed primary therapy -defined as failing two induction chemotherapies, (b) have relapsed or (c) are not suitable for intensive induction chemotherapy will be eligible. or

Datentyp

boolean

Alias
UMLS CUI [1]
C0023467
patients with aml blast crisis from cml if they are not suitable candidates for intensive induction chemotherapy or have failed imatinib mesylate or
Beschreibung

AML blast crisis from CML

Datentyp

boolean

Alias
UMLS CUI [1]
C0023474
patients with secondary aml after mds if they are not suitable candidates for intensive induction chemotherapy.
Beschreibung

secondary aml after mds

Datentyp

boolean

Alias
UMLS CUI [1]
C3463824
ecog 0,1,2, or 3
Beschreibung

ECOG performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
life expectancy > 12 weeks.
Beschreibung

life expectancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0023671
adequate renal and hepatic function
Beschreibung

renal and hepatic function

Datentyp

boolean

Alias
UMLS CUI [1]
C0232804
UMLS CUI [2]
C0232741
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
uncontrolled central nervous system involvement by aml
Beschreibung

uncontrolled central nervous system involvement by aml

Datentyp

boolean

Alias
UMLS CUI [1]
C3714787
active cardiovascular disease as defined by nyha class iii-iv categorization.
Beschreibung

NYHA

Datentyp

boolean

Alias
UMLS CUI [1]
C1275491
intercurrent illness or medical condition precluding safe administration of ribavirin.
Beschreibung

intercurrent illness or medical condition precluding safe administration of ribavirin

Datentyp

boolean

Alias
UMLS CUI [1]
C0035525
received any previous therapy within 28 days prior to study entry.hydrea is permitted but must be stopped 7 days prior to starting study drug.
Beschreibung

received any previous therapy within 28 days prior to study entry.hydrea is permitted but must be stopped 7 days prior to starting study drug

Datentyp

boolean

Alias
UMLS CUI [1]
C0020402
known infection with hiv.
Beschreibung

HIV

Datentyp

boolean

Alias
UMLS CUI [1]
C0019682

Ähnliche Modelle

Eligibility Acute Myelocytic Leukemia NCT00559091

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
AML diagnosis
Item
a diagnosis of acute myeloid leukemia (aml), either m4 or m5 subtype de novo or resulting from a transformation from mds or a myeloproliferative disorder.
boolean
C0023467 (UMLS CUI [1])
patients with aml who (a) have failed primary therapy -defined as failing two induction chemotherapies, (b) have relapsed or (c) are not suitable for intensive induction chemotherapy will be eligible. or
Item
patients with aml who (a) have failed primary therapy -defined as failing two induction chemotherapies, (b) have relapsed or (c) are not suitable for intensive induction chemotherapy will be eligible. or
boolean
C0023467 (UMLS CUI [1])
AML blast crisis from CML
Item
patients with aml blast crisis from cml if they are not suitable candidates for intensive induction chemotherapy or have failed imatinib mesylate or
boolean
C0023474 (UMLS CUI [1])
secondary aml after mds
Item
patients with secondary aml after mds if they are not suitable candidates for intensive induction chemotherapy.
boolean
C3463824 (UMLS CUI [1])
ECOG performance status
Item
ecog 0,1,2, or 3
boolean
C1520224 (UMLS CUI [1])
life expectancy
Item
life expectancy > 12 weeks.
boolean
C0023671 (UMLS CUI [1])
renal and hepatic function
Item
adequate renal and hepatic function
boolean
C0232804 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
uncontrolled central nervous system involvement by aml
Item
uncontrolled central nervous system involvement by aml
boolean
C3714787 (UMLS CUI [1])
NYHA
Item
active cardiovascular disease as defined by nyha class iii-iv categorization.
boolean
C1275491 (UMLS CUI [1])
intercurrent illness or medical condition precluding safe administration of ribavirin
Item
intercurrent illness or medical condition precluding safe administration of ribavirin.
boolean
C0035525 (UMLS CUI [1])
received any previous therapy within 28 days prior to study entry.hydrea is permitted but must be stopped 7 days prior to starting study drug
Item
received any previous therapy within 28 days prior to study entry.hydrea is permitted but must be stopped 7 days prior to starting study drug.
boolean
C0020402 (UMLS CUI [1])
HIV
Item
known infection with hiv.
boolean
C0019682 (UMLS CUI [1])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video